Novartis insists its flu vaccines are safe

October 25, 2012

Swiss pharmaceutical giant Novartis insisted early Thursday that its flu vaccines were safe despite a sales ban by Italy, Switzerland and Austria.

"Novartis confirms its confidence in the safety and efficacy of its seasonal Agrippal and Fluad," the company said in a statement released overnight.

On Wednesday, Italian, Swiss and Austrian authorities stopped sales of the vaccines pending tests into possible side effects.

The alarm was first raised in Italy after white particles were seen in syringes carrying the vaccines, but Novartis stressed that "these particles can occur in the vaccine manufacturing process," adding it was "confident that there is no impact on the safety or efficacy of the vaccine."

The company said it had voluntarily provided Italian health authorities with its assessments "supporting the quality, efficacy and safety" of the vaccines, and that it would continue working with them in a bid to understand their decision to put a freeze on the vaccines.

Shortly after the Italian decision, the Swiss national drug agency Swissmedic also ordered an "immediate halt" of the vaccines due to "possible impurities", and were followed by Austrian .

The Swiss decision affects some 160,000 , Swissmedic said.

Novartis meanwhile stressed that it was "fully committed to providing high quality vaccines to patients and will continue to work with the authorities to make vaccines available."

Explore further: Italy, Switzerland, Austria freeze sales of Novartis flu vaccines

Related Stories

Italy, Switzerland, Austria freeze sales of Novartis flu vaccines

October 24, 2012
Italian, Swiss and Austrian authorities on Wednesday halted the sale of flu vaccines made by Swiss pharmaceutical giant Novartis.

New development could increase flu vaccine supply

June 2, 2011
(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or compound ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

gord4356
not rated yet Oct 27, 2012
I was with the Canadian Forces in 2009, was ordered to get the H1N1 shot (AREPANRIX by GSK GlaxoSmithKline) and had an adverse reaction to the vaccine. I received PERMANENT neurological, cardiovascular, gastrointestinal, and respiratory symptoms: dizziness, vertigo, irregular heart rhythms, shortness of breath, muscle weakness and pain, and numbness in hands and feet. My physical fitness changed from special forces fit to that of a 70 year old in a matter of days.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.